Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September, Zevra has locked in a deal to sell the voucher for $150 million. The cash from the sale will be used to fuel R&D, plus the commercial rollouts of Miplyffa and the urea cycle disorder medicine Olpruva, which Zevra picked up in its $91 million buyout of Acer Therapeutics, the company said.
After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September, Zevra has locked in a deal to sell the voucher for $150 million. The cash from the sale will be used to fuel R&D, plus the commercial rollouts of Miplyffa and the urea cycle disorder medicine Olpruva, which Zevra picked up in its $91 million buyout of Acer Therapeutics, the company said.
